Tumor Immune Microenvironment in Non-Small Cell Lung Cancer

The tumour immune microenvironment in non-small cell lung cancer (NSCLC) comprises a complex network of malignant cells, stromal elements and a diverse array of immune infiltrates whose composition and spatial organisation critically influence disease progression and therapy response. Key players include tumour-infiltrating lymphocytes (TILs), comprising cytotoxic CD8+ T cells, helper CD4+ T cells and regulatory subsets, as well as antigen-presenting cells such as dendritic cells and macrophages adopting pro-inflammatory (M1) or immunosuppressive (M2) phenotypes. The functional state of T cells—activated, exhausted or anergic—depends on immune-checkpoint pathways and local cytokine milieus. Classification of tumours into inflamed, immune-excluded or desert phenotypes based on the density and localisation of immune cells enables patient stratification for immunotherapy. Standard treatments, including neoadjuvant chemotherapy, can remodel the microenvironment by enhancing antigen presentation and lymphocyte infiltration. Advances in high-dimensional imaging and computational pathology now permit quantitative mapping of cellular niches and predictive biomarker development, offering new avenues for personalised immunomodulatory strategies.

Research from Nature Portfolio

Recent studies have utilised high-plex imaging and spatial analysis to delineate the cellular geography of NSCLC lesions. One investigation mapped 23 markers on multiplex immunofluorescence panels to define unmixed clusters dominated by immunoprotective lymphocytes versus mixed clusters enriched in immunosuppressive elements. Distance metrics revealed that T cells bearing checkpoint molecules preferentially localise near tumour cells, enabling classification of inflamed and non-inflamed tumours with clear survival implications. A foundational computational gene-expression analysis further partitioned NSCLC into immune-competent and immune-defective subtypes across both adenocarcinomas and squamous carcinomas, highlighting the pivotal roles of tumour-associated macrophages and regulatory B cells in modulating cytotoxic T-cell activity and shaping clinical response to checkpoint blockade.

Tumor Immune Microenvironment in Non-Small Cell Lung Cancer publication trend

The graph below shows the total number of articles in tumor immune microenvironment in non-small cell lung cancer across all publications each year (not limited to Nature Index journals).

Technical terms

Tumour immune microenvironment (TIME): The dynamic ecosystem of tumour, stromal and immune cells, plus signalling molecules and extracellular matrix, that surrounds and interacts with malignant cells.

Tumour-infiltrating lymphocytes (TILs): Immune cells, predominantly T cells, that have migrated into the tumour and mediate antitumour immunity or suppression.

Immune checkpoint: A regulatory pathway in T cells (e.g. PD-1/PD-L1) that modulates immune activation and can be exploited by tumours to evade immunity.

Tumour-associated macrophage (TAM): Macrophages within the tumour that can adopt pro-inflammatory (M1) or immunosuppressive (M2) phenotypes influencing tumour progression.

Multiplex immunofluorescence: A technique that uses multiple fluorescent markers simultaneously to visualise and quantify various cell types and proteins in tissue sections.

Computational pathology: Application of machine-learning algorithms to digital pathology images to extract quantitative information on tissue architecture and cell phenotypes.

References

1. Immune cellular patterns of distribution affect outcomes of patients with non-small cell lung cancer. Nature Communications (2023).
2. High post‐chemotherapy TIL and increased CD4+TIL are independent prognostic factors of surgically resected NSCLC following neoadjuvant chemotherapy. MedComm (2023).
3. Deep computational image analysis of immune cell niches reveals treatment-specific outcome associations in lung cancer. npj Precision Oncology (2023).
4. Multiplex immunofluorescence and single‐cell transcriptomic profiling reveal the spatial cell interaction networks in the non‐small cell lung cancer microenvironment. Clinical and Translational Medicine (2023).
5. Spatial insights into immunotherapy response in non-small cell lung cancer (NSCLC) by multiplexed tissue imaging. Journal of Translational Medicine (2024).